Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Johnson & Johnson : J&J Chairman Weldon's Salary Cut To $1 Million After Stepping Down As CEO

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/07/2012 | 11:51pm CEST
   By Peter Loftus 
   Of  
 

Johnson & Johnson (JNJ) Chairman William Weldon's annual base salary was reduced by nearly half to $1 million after he stepped down as chief executive last month, the company said Monday.

Weldon's previous annual base salary was set at $1.97 million for 2012, for his roles as both chairman and CEO, but with the expectation that J&J's board would consider the appropriate compensation for Weldon in his role as chairman only.

The decrease reflects that Weldon is no longer CEO, said spokesman Al Wasilewski.

On April 26, Alex Gorsky succeeded Weldon as CEO. Weldon is continuing as chairman and will remain an employee of the company, J&J said in a quarterly report filed with the Securities and Exchange Commission Monday.

J&J said in a previous SEC filing that in his role as chairman, Weldon will work closely with Gorsky to ensure a seamless leadership transition. During this time, all day-to-day management and operational responsibilities are being transferred to Gorsky.

Weldon will remain an employee but not a member of the J&J executive committee, which is the principal management group responsible for strategic operations and allocations of the resources of the company.

Weldon's main duties as chairman will include working with the board of directors, facilitating communication between the board and management, assisting Gorsky in business planning and strategy, representing the company before governmental and other organizations, and serving as chairman of the board's finance committee.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
05/27 JOHNSON & JOHNSON : Attorney General Becerra Announces $33M Nationwide Settlemen..
05/27 JOHNSON & JOHNSON : 3 Value Stocks for Every Investor
05/27 PFIZER : FDA panel backs Pfizer biosim to blockbuster anemia meds from Amgen, Jo..
05/26 JOHNSON & JOHNSON : W.Va. to receive $440,000 in product quality settlement
05/26 JOHNSON & JOHNSON : Illinois to receive $1M of Johnson & Johnson settlement
05/26 JOHNSON & JOHNSON : First-Ever Families +SocialGood Convenes Advocates, Celebrit..
05/26 Janssen plans to expand pharma investment in China
05/26 HAVAS : Group acquires healthcare agency Sorento
05/26 JOHNSON & JOHNSON : Va. to receive about $777K in settlement over medicines Virg..
05/26 JOHNSON & JOHNSON : pagará millones por venta de medicinas adulteradas
More news
Sector news : Pharmaceuticals - NEC
05/26DJSUN PHARMACEUTICAL INDUSTRIES : Pharma 4Q Profit Falls 13.6%
05/24 FTSE edges up helped by M&S, but miners weigh
05/23DJMERCK : FDA OKs Merck's Keytruda to Treat Cancers With Genetic Defects -- Update
05/23DJMERCK : FDA Approves Merck's Keytruda to Treat Cancers With Genetic Defects
05/23DJALEXION PHARMACEUTICALS : Shakeup Continues as Four Executives Exit -- 2nd Updat..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
05/26 RETIREMENT STRATEGY : Making Money Without Spending A Penny Out Of Pocket!
05/26 Time For Tau - For Now
05/26 Putting My Core Conviction Stocks To The Test
05/25 THE GOOD BUSINESS PORTFOLIO : 2017 1st Quarter Earnings And Performance Review
05/25 Re-Evaluating And Identifying Our Core Holdings
Advertisement
Financials ($)
Sales 2017 75 643 M
EBIT 2017 23 480 M
Net income 2017 17 895 M
Debt 2017 8 113 M
Yield 2017 2,65%
P/E ratio 2017 19,36
P/E ratio 2018 17,39
EV / Sales 2017 4,63x
EV / Sales 2018 4,40x
Capitalization 341 901 M
More Financials
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 130 $
Spread / Average Target 2,6%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON10.69%341 901
ROCHE HOLDING LTD.14.88%236 581
NOVARTIS AG6.75%211 457
PFIZER INC.-1.05%191 398
MERCK & CO., INC.10.28%177 567
SANOFI13.54%123 549
More Results